Current Clinical Trials

In this research study, we want to learn about the safety of the study drugs, ribociclib and everolimus, when given together at different doses after radiation therapy. We also want to learn about the effects, if any, these drugs have on children and young adults with brain tumors.

We are asking people to be in this research study who have been diagnosed with a high grade glioma, their tumor has been screened for the Rb1 protein, and they have recently finished radiation therapy. If a patient has DIPG or a Bi-thalamic high grade glioma, they do not need to have the tumor tissue screened for the Rb1 protein, but do need to have finished radiation therapy.

Tumor cells grow and divide quickly. In normal cells, there are proteins that control how fast cells grow but in cancer cells these proteins no longer work correctly making tumor cells grow quickly. Both study drugs work in different ways to slow down the growth of tumor cells. The researchers think that if the study drugs are given together soon after radiation therapy, it may help improve the effect of the radiation in stopping or slowing down tumor growth.

The study drugs, ribociclib and everolimus, have been approved by the United States Food and Drug Administration (FDA). Ribociclib is approved to treat adults with breast cancer and everolimus is approved for use in adults and children who have other types of cancers. The combination of ribociclib and everolimus has not been tested in children or in people with brain tumors and is considered investigational.

In this research study the investigators want to learn more about the safety of the study drug, PTC596 has when taken during radiation. The investigators also want to learn about the effects, if any, these drugs have on children and young adults with brain tumors.

The investigators are asking people to be in this research study who have been diagnosed with a high grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG) to be in the research, because they have scheduled to have radiation to treat their cancer.

The study is divided into two parts. The goal of the first part is to find the dose of PTC596 that can be given with radiation without causing serious side effects. The purpose of this surgical study is to test the amount of a study drug that may be found in the tumor and blood when given prior to and during a planned surgery for removal of the recurrent tumor.

In this research study, we want to learn more about the effects of the study drug larotrectinib on children with brain tumors. We want to learn how well it works to shrink brain tumors when used alone or when given with standard chemotherapy or after radiation therapy.

The investigators are asking people to be in this research study who have been diagnosed with a high-grade glioma with a certain abnormal gene called NTRK. The investigators will evaluate the disease of the patients after they take the larotrectinib for 2 cycles. After taking the study drug for 2 cycles, the investigators will determine the next course of treatment. Patients will continue to receive either larotrectinib alone, larotrectinib with standard chemotherapy or larotrectinib alone after radiation therapy. The length of treatment depends on how well the patient is doing and which standard treatment the doctor thinks is best for them.

There is also a surgical cohort of the study where tumor samples and blood samples will be collected and sent to researchers to determine if larotrectinib is found in the tumor and how much is in the blood.

The purpose of this study is to learn about the effects of the study drug tocilizumab in patients with Adamantinomatous craniopharyngioma (ACP). We think this drug can benefit ACP patients who may or may not have undergone surgery or radiation as it may help shrink this type of brain tumor or slow its growth.

We are asking individuals to be in this research study if they have been diagnosed with ACP that has increased in size or is unable to be removed entirely by surgery.

Tocilizumab is a form of targeted immunosuppressive therapy and is given as a liquid through an intravenous (IV) infusion once every 2 weeks. The drug is approved by the United States Food and Drug administration (FDA) for a different disease in children.

In this research study, we want to find out if the study drug Lutathera is effective in treating different kinds of brain cancer. We also want to find the safest dose of this drug that does not cause serious side effects.

We are asking the participation of children and young adults who have been diagnosed with either a high-grade brain or spine tumor or a meningioma that expresses a specific protein called somatostatin receptor on its surface. This is confirmed with a special type of scan called a DOTATATE PET.

Lutathera is a form of targeted radiation therapy and is given by intravenous (IV) infusion once every 2 months. This drug is approved by the FDA (Food and Drug Administration) for the treatment of another type of cancer but it has not yet been approved for the treatment of brain/spine tumors.

The purpose of this study is to learn more about the effects of the study drug binimetinib in patients with Adamantinomatous craniopharyngioma (ACP). We think this drug can benefit ACP patients who may or may not have undergone surgery or radiation as it may help shrink this type of brain tumor or slow its growth. This is based on laboratory studies on cells grown in the lab from craniopharyngioma tumor tissue collected from patients at surgery.

We are asking individuals to be in this research study if they have been diagnosed with ACP that has increased in size or is unable to be removed entirely by surgery.

Binimetinib is a form of targeted chemotherapy and is given orally as a tablet twice a day. This drug is approved by the United States Food and Drug administration (FDA) to treat a different disease in children and adults.